PASIREOTIDE CAS 396091-73-9

Product Description:

Product Name: PASIREOTIDE CAS NO: 396091-73-9

Synonyms:

Cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[(2-aminoethyl)amino]carbonyl]oxy]-L-prolyl];

[(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate;

Chemical & Physical Properties:

Appearance: Crystalline solid

Assay :≥99.00%

Density: 1.4±0.1 g/cm3

Boiling Point: 1351.4±65.0℃ at 760 mmHg

Flash Point: 771.1±34.3℃

Vapour Pressure: 0.0±0.3 mmHg at 25℃

Index of Refraction: 1.680

Pasireotide (SOM230, trade name Signifor) is an orphan drug approved in the U.S. and Europe for the treatment of Cushing's disease and acromegaly in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.

Pasireotide was approved for Cushing's disease by the EMEA in October 2009 and by the FDA in December 2012.Pasireotide LAR was approved by the FDA for treatment of acromegaly in December 2014, and had been approved for this indication by the EMEA one month earlier.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.